The irritable bowel syndrome (IBS) is a chronic disorder of gut-brain interaction. IBS is still associated with areas of uncertainties, especially regarding the optimal diagnostic work-up and the more appropriate management. Experts from 7 Italian Societies conducted a Delphi consensus with literature summary and voting process on 27 statements. Recommendations and quality of evidence were evaluated using the grading of recommendations, assessment, development, and evaluation (GRADE) criteria. Consensus was defined as >80% agreement and reached for all statements. In terms of diagnosis, the consensus supports a positive diagnostic strategy with a symptom-based approach, including the psychological comorbidities assessment and the exclusion of alarm symptoms, together with the digital rectal examination, full blood count, C-reactive protein, serology for coeliac disease, and fecal calprotectin assessment. Colonoscopy should be recommended in patients with alarm features. Regarding treatment, the consensus strongly supports a dietary approach for patients with IBS, the use of soluble fiber, secretagogues, tricyclic antidepressants, psychologically directed therapies and, only in specific IBS subtypes, rifaximin. A conditional recommendation was achieved for probiotics, polyethylene glycol, antispasmodics, selective serotonin reuptake inhibitors and, only in specific IBS subtypes, 5-HT3 antagonists, 5-HT4 agonists, bile acid sequestrants.

Italian guidelines for the management of irritable bowel syndrome. Joint Consensus from the Italian Societies of: Gastroenterology and Endoscopy (SIGE), Neurogastroenterology and Motility (SINGEM), Hospital Gastroenterologists and Endoscopists (AIGO), Digestive Endoscopy (SIED), General Medicine (SIMG), Gastroenterology, Hepatology and Pediatric Nutrition (SIGENP) and Pediatrics (SIP) / Barbara, Giovanni; Cremon, Cesare; Bellini, Massimo; Corsetti, Maura; Di Nardo, Giovanni; Falangone, Francesca; Fuccio, Lorenzo; Galeazzi, Francesca; Iovino, Paola; Sarnelli, Giovanni; Savarino, Edoardo Vincenzo; Stanghellini, Vincenzo; Staiano, Annamaria; Stasi, Cristina; Tosetti, Cesare; Turco, Rossella; Ubaldi, Enzo; Zagari, Rocco Maurizio; Zenzeri, Letizia; Marasco, Giovanni. - 55:2(2023), pp. 187-207. [10.1016/j.dld.2022.11.015]

Italian guidelines for the management of irritable bowel syndrome. Joint Consensus from the Italian Societies of: Gastroenterology and Endoscopy (SIGE), Neurogastroenterology and Motility (SINGEM), Hospital Gastroenterologists and Endoscopists (AIGO), Digestive Endoscopy (SIED), General Medicine (SIMG), Gastroenterology, Hepatology and Pediatric Nutrition (SIGENP) and Pediatrics (SIP)

Di Nardo, Giovanni;Zenzeri, Letizia;
2023

Abstract

The irritable bowel syndrome (IBS) is a chronic disorder of gut-brain interaction. IBS is still associated with areas of uncertainties, especially regarding the optimal diagnostic work-up and the more appropriate management. Experts from 7 Italian Societies conducted a Delphi consensus with literature summary and voting process on 27 statements. Recommendations and quality of evidence were evaluated using the grading of recommendations, assessment, development, and evaluation (GRADE) criteria. Consensus was defined as >80% agreement and reached for all statements. In terms of diagnosis, the consensus supports a positive diagnostic strategy with a symptom-based approach, including the psychological comorbidities assessment and the exclusion of alarm symptoms, together with the digital rectal examination, full blood count, C-reactive protein, serology for coeliac disease, and fecal calprotectin assessment. Colonoscopy should be recommended in patients with alarm features. Regarding treatment, the consensus strongly supports a dietary approach for patients with IBS, the use of soluble fiber, secretagogues, tricyclic antidepressants, psychologically directed therapies and, only in specific IBS subtypes, rifaximin. A conditional recommendation was achieved for probiotics, polyethylene glycol, antispasmodics, selective serotonin reuptake inhibitors and, only in specific IBS subtypes, 5-HT3 antagonists, 5-HT4 agonists, bile acid sequestrants.
2023
constipation; diarrhea; disorders of gut-brain interaction; irritable bowel syndrome
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Italian guidelines for the management of irritable bowel syndrome. Joint Consensus from the Italian Societies of: Gastroenterology and Endoscopy (SIGE), Neurogastroenterology and Motility (SINGEM), Hospital Gastroenterologists and Endoscopists (AIGO), Digestive Endoscopy (SIED), General Medicine (SIMG), Gastroenterology, Hepatology and Pediatric Nutrition (SIGENP) and Pediatrics (SIP) / Barbara, Giovanni; Cremon, Cesare; Bellini, Massimo; Corsetti, Maura; Di Nardo, Giovanni; Falangone, Francesca; Fuccio, Lorenzo; Galeazzi, Francesca; Iovino, Paola; Sarnelli, Giovanni; Savarino, Edoardo Vincenzo; Stanghellini, Vincenzo; Staiano, Annamaria; Stasi, Cristina; Tosetti, Cesare; Turco, Rossella; Ubaldi, Enzo; Zagari, Rocco Maurizio; Zenzeri, Letizia; Marasco, Giovanni. - 55:2(2023), pp. 187-207. [10.1016/j.dld.2022.11.015]
File allegati a questo prodotto
File Dimensione Formato  
Barbara_Italian-guidelines-for the management_2023.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.29 MB
Formato Adobe PDF
1.29 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1668294
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 14
social impact